Literature DB >> 6849774

Determinants of the plasma protein binding of theophylline in health.

D Buss, D Leopold, A P Smith, P A Routledge.   

Abstract

1 The plasma protein binding of theophylline was determined after addition of [14C]-theophylline (15 micrograms/ml) to plasma from 24 healthy drug-free volunteers and equilibrium dialysis for 2 h at 37 degrees C. 2 The percentage of drug unbound was 60.0% +/- 2.2% (s.d.) with very little variation between individuals. The binding ratio of theophylline was not significantly related to the plasma albumin or alpha 1-acid glycoprotein (AAG) concentrations but was significantly, although weakly, negatively related to the logarithm of the non-esterified fatty acid concentration (NEFA) (r = 0.443, P less than 0.05). 3 Intravenous administration of heparin (1000 units) caused a significant rise in plasma NEFA concentration and in the percentage of drug unbound in plasma after equilibrium dialysis. 4 In human serum albumin solutions, the binding ratio of theophylline was significantly related to the albumin concentration and at the albumin concentration seen in the 24 normal subjects, the percentage of drug unbound was almost identical. Addition of AAG in physiological concentrations did not enhance theophylline binding but oleic acid, and to a lesser extent palmitic acid, reduced binding significantly. 5 The percentage of theophylline unbound in plasma varied markedly with pH so that at pH7 the percentage unbound was 52% greater than at pH 8. There was no evidence of concentration dependence of binding up to 140 micrograms/ml theophylline. 6 Theophylline appears to bind almost exclusively to albumin and its plasma protein binding varies little in healthy subjects, showing no concentration-dependence over the therapeutic range of concentrations. The binding is affected by pH and by NEFA concentration, however, and these factors may be of greater importance in disease states. Caution should be employed in the use of heparin in studies of plasma protein binding of theophylline.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849774      PMCID: PMC1427801          DOI: 10.1111/j.1365-2125.1983.tb01521.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  THE COLORIMETRIC MICRO-DETERMINATION OF NON-ESTERIFIED FATTY ACIDS IN PLASMA.

Authors:  W G DUNCOMBE
Journal:  Clin Chim Acta       Date:  1964-02       Impact factor: 3.786

2.  Pharmacokinetic aspects of theophylline in premature newborns.

Authors:  J V Aranda; D S Sitar; W D Parsons; P M Loughnan; A H Neims
Journal:  N Engl J Med       Date:  1976-08-19       Impact factor: 91.245

Review 3.  Pharmacokinetics and temperature.

Authors:  B E Ballard
Journal:  J Pharm Sci       Date:  1974-09       Impact factor: 3.534

4.  Electroimmuno assay.

Authors:  C B Laurell
Journal:  Scand J Clin Lab Invest Suppl       Date:  1972

5.  Influence of free fatty acid concentration on drug binding to plasma albumin.

Authors:  A A Spector; E C Santos; J D Ashbrook; J E Fletcher
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

6.  Relationship between theophylline concentration in plasma and saliva of man.

Authors:  R Koysooko; E F Ellis; G Levy
Journal:  Clin Pharmacol Ther       Date:  1974-05       Impact factor: 6.875

7.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

8.  Development of large-scale fractionation methods. IV. A simple method for the large-scale preparation of alpha1-acid glycoprotein.

Authors:  Y L Hao; M Wickerhauser
Journal:  Biochim Biophys Acta       Date:  1973-09-21

9.  A rapid micromethod for measuring theophylline in serum by reverse-phase high-performance liquid chromatography.

Authors:  S J Soldin; J G Hill
Journal:  Clin Biochem       Date:  1977-04       Impact factor: 3.281

10.  Pharmacokinetics of theophylline in hepatic disease.

Authors:  A Mangione; T E Imhoff; R V Lee; L Y Shum; W J Jusko
Journal:  Chest       Date:  1978-05       Impact factor: 9.410

View more
  11 in total

1.  Pharmacokinetics of theophylline and its metabolites in a patient undergoing continuous ambulatory peritoneal dialysis.

Authors:  T B Vree; M Martea; R G Tiggeler; Y A Hekster; J C Hafkenscheid
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

2.  Do saliva concentrations predict plasma unbound theophylline concentrations? A problem re-examined.

Authors:  C Knott; M Bateman; F Reynolds
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

3.  Protein binding of theophylline.

Authors:  D C Buss; P Ebden; S Baker; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

Review 4.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

5.  Variability of the serum protein binding of theophylline in patients with asthma and cystic fibrosis.

Authors:  J Blanchard; S Harvey; W J Morgan
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

6.  Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.

Authors:  E Lunell; O Borgå; R Larsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  The protein binding of timegadine determined by equilibrium dialysis.

Authors:  S George; A McBurney; J Ward
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

8.  Free and total plasma theophylline concentrations in chronic airflow obstruction.

Authors:  P Ebden; D Leopold; A P Smith; D Buss; P A Routledge
Journal:  Thorax       Date:  1984-05       Impact factor: 9.139

Review 9.  Hypoxia, arterial pH and theophylline disposition.

Authors:  M Richer; Y W Lam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

10.  The ex vivo plasma protein binding of theophylline in renal disease.

Authors:  D Leopold; D Webb; D C Buss; R A Fifield; A P Smith; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.